

---

# Helping researchers spot game-changing drug candidates

Categories : [News](#), [Pharmaceuticals](#)

Date : 30. March 2021

## NanoTemper Technologies and PharmAI develop biophysical tools for the analysis of huge amounts of data in drug research

A cooperation now underway between Dresden-based start-up PharmAI and Munich-based NanoTemper Technologies aims to do just that. In the future, the two partners will combine their know-how in innovative products. Among other things, these will enable small laboratories to enter the field of active ingredient research. For example, this would make it possible to conduct more research into drugs for rare diseases, the development of which is currently rather unprofitable for large pharmaceutical companies.

NanoTemper Technologies has been a leader in the development of devices and software solutions for the analysis of biomolecules for years. To this end, the Munich-based company combines various optical measurement methods that use light to make important statements about molecules: about their size, composition, durability or potential use as an active ingredient. The DiscoveryEngine software, in turn, uses artificial intelligence to find suitable drug candidates in large databases based on protein structure data. "We now want to bundle these competencies to create added value for our customers," explains Dr. Philipp Baaske, one of the two managing directors of NanoTemper Technologies.

Virtual screening, he says, is where the future lies. "However, customers don't want to spend time dealing with measured values; they want to gain new insights and use them in their work. That's exactly what we help with." For Dr. Joachim Haupt, CEO of PharmAI, the collaboration is therefore a next logical step. "Our software makes helpful predictions about drug candidates and reduces millions of possibilities to a manageable size," he explains. The particular devices and software are able to validate those predictions afterwards, he says, so customers can move forward with the results directly.

In the coming months, the companies will combine their technologies to develop a new generation of tools. "This will make us an enabler, because these products will enable the entire industry to move forward and do things that are impossible today," Baaske is convinced. For the company, the cooperation also opens up market areas in which the startup has not yet been active. "The collaboration enables us to apply our software to new problems and is therefore extremely exciting for us," Haupt adds. His team is looking forward to working together.

"Bringing life-saving drugs and therapies to market is more important than ever. In order to make big leaps in research quickly, the focus for these new drug development tools is reliability and ease of use, so they can be used by as many people as possible. Through this collaboration, we are able to focus our products on what researchers need to be successful."

- Philipp Baaske, Co-CEO of NanoTemper Technologies

Both CEOs are convinced that these tools will help to develop drugs and new therapies in a much shorter time and at a lower cost in the future.